A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE Trial
Arvin K. George(Johns Hopkins University), Jonathan Coleman(Memorial Sloan Kettering Cancer Center), Thomas J. Polascik(Duke University), Ranko Miocinovic(DuPage Medical Group), Amit R. Patel(University of Virginia), Andres Correa(Fox Chase Cancer Center), Ardeshir R. Rastinehad(Royal Free London NHS Foundation Trust), Srinivas Vourganti(Rush University Medical Center), Wayne Brisbane(University of California, Los Angeles), Derek J. Lomas(Mayo Clinic in Arizona), Jeffrey Gahan, Al B. Barqawi(University of Colorado Anschutz Medical Campus), Alice Yu(Moffitt Cancer Center), Michael J. Schwartz(Northwell Health), Abhinav Sidana(Johns Hopkins Medicine), David Y. T. Chen(Fox Chase Cancer Center), Brian T. Helfand(NorthShore University HealthSystem), Edward Uchio(University of California, Irvine), Timothy McClure(Cornell University), James Wysock(New York University)
Cited by 15
Related Papers
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
|Cancer Cell|2021|453
An overview of kidney stone imaging techniques
|Nature Reviews Urology|2016|389
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
|Journal of Clinical Oncology|2020|280